precision oncology

Treatment with GLP-1 receptor agonists (GLP-1RAs) was associated with a significantly lower risk of progression to metastatic disease in non–small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). The study, presented at the 2026 American…

Twenty-five years after imatinib transformed chronic myeloid leukaemia from a fatal diagnosis into a manageable disease for many patients, Brian Druker reflects on the curiosity, setbacks, and patients who shaped one of oncology's greatest breakthroughs. Long before I understood the…

Daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. For Dr Eileen O’Reilly, the result is not simply a remarkable curve on a conference screen, but the beginning of a new way to think about a disease long…

Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…

Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…

From crowded oncology wards in Cairo to international leadership in cancer education, Dr. Mohamed Emam Sobeih has built a career shaped by one central belief: treating cancer requires more than medicine alone. At the National Cancer Institute Egypt, where Dr…

Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…

As cancer survival improves, a critical gap persists: the period after treatment, where psychological distress, identity disruption, and unmet needs remain insufficiently addressed in routine oncology care. A System Designed for Treatment, Not Transition “We have to be next to…

In oncology, progress is measured in survival rates, response curves, and treatment gains. But those numbers rest on a quieter assumption: that health systems can deliver what science makes possible. When they cannot, progress becomes uneven—not in discovery, but in…

In oncology, some ideas arrive too early. For decades, cancer vaccines were one of them. The concept was elegant: train the immune system to recognise tumour cells, much like it recognises viruses, and allow it to eliminate disease with precision…